Company intelligence / Profile preview
Ikarovec
Colney/Norwich Research Park, Norfolk, United Kingdomikarovec.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Ikarovec has developed a unique bicistronic gene therapy approach targeting complex eye diseases such as AMD. Their preclinical data suggest superiority over current and in-development treatments. The company aims to provide a one-time treatment that could offer lifelong benefit and reduce the burden of frequent injections required by current standards of care. They have raised £8M in seed funding and are seeking Series A investment to advance into clinical trials.
- Therapeutic areas
- Ophthalmology
- Modalities
- Gene therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Rentschler Biopharma (for manufacturing/development support)LifeArcParkwalk AdvisersUKI2S as investors/partners supporting early development/funding rounds
Beyond the preview
Go deeper on Ikarovec.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ikarovec.